Sapalidis Konstantinos, Sardeli Chrysanthi, Pavlidis Efstathios, Koimtzis Georgios, Koulouris Charilaos, Michalopoulos Nikolaos, Mantalovas Stylianos, Tsiouda Theodora, Passos Ioannis, Kosmidis Christoforos, Giannakidis Dimitrios, Surlin Valeriu, Katsaounis Athanasios, Alexandrou Vyron, Amaniti Aikaterini, Zarogoulidis Paul, Huang Haidong, Li Qiang, Mogoanta Stelian, Kesisoglou Isaac
Third Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
J Cancer. 2019 Jan 30;10(4):810-818. doi: 10.7150/jca.30300. eCollection 2019.
Lung cancer still remains diagnosed at a late stage although we have novel diagnostic techniques at our disposal. However; for metastatic disease we have novel therapies based on pharmacogenomics. Tumor heterogenity provides us different treatments. There are several reasons for carcinogenesis; fibrosis and scar tissue provides an environment that induces malignancy. In the current review we will try and elucidate the pathways involved from scar tissue to carcinogenesis.
尽管我们拥有多种新颖的诊断技术，但肺癌仍常被诊断为晚期。然而，对于转移性疾病，我们有基于药物基因组学的新型疗法。肿瘤异质性为我们提供了不同的治疗方法。致癌的原因有多种；纤维化和瘢痕组织提供了诱发恶性肿瘤的环境。在本综述中，我们将试图阐明从瘢痕组织到致癌过程中涉及的途径。
